Risk of cardiovascular mortality in patients with gastric cancer
1. In this cohort of patients with gastric cancer, there was a significantly higher risk of cardiovascular death compared with ...
Tag: oncology
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup – Breakthrough ALS gene therapy, new adult pneumonia vaccine, needle-free obesity treatment, and Pfizer’s business overhaul [October 28, 2025]
Amryta’s Sodesta gene therapy gains accelerated approval for ALS The Food and Drug Administration has granted accelerated approval to Sodesta, ...
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial
1. In patients with previously treated extensive-stage small-cell lung cancer (ES-SCLC), treatment with ifinatam deruxtecan (I-DXd) showed promising efficacy with ...
Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study
1. When compared with inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA), dupilumab treatment was associated with an increased risk of ...
Artificial intelligence accelerates drug discovery and reduces animal testing
1. Artificial intelligence is cutting preclinical development timelines from more than three years to under two years. 2. The Food ...
Royalty financing deepens exposure to small cell lung cancer revenues
1. Royalty Pharma struck a deal worth up to 950 million dollars to buy into Amgen’s DLL3 directed bispecific for ...
Moderate to severe TBI is associated with elevated malignant brain tumor risk
1. In this retrospective cohort study, moderate to severe traumatic brain injury (TBI) was associated with an increased risk of ...
2 Minute Medicine Rewind September 1, 2025
β-Blocker Use and Health Status Among Patients With Heart Failure With Preserved Ejection Fraction 1. In patients with heart failure ...
Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer
1. In patients with ER-positive, HER2-negative advanced breast cancer who developed an ESR1 mutation during first-line aromatase inhibitor plus CDK4/6 ...
Vepdegestrant extends progression-free survival in ER-positive, HER2-negative breast cancer
1. In this randomized controlled trial, vepdegestrant achieved a longer progression-free survival than fulvestrant in patients with advanced ER-positive, HER2-negative ...
